Emerging Company in the Spotlight sponsored by JFK Communications.
Congratulations to Insmed, BioNJ’s Emerging Company in the Spotlight for September. Each month we will feature a BioNJ Member who is progressively growing and evolving within the New Jersey biotechnology industry. So many of our Members are making a dramatic impact on our State’s innovative ecosystem. And, for that we say thank you.
Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. The company currently employs approximately 115 people, with the aim to employ more than 150 by early 2016.
Patients who suffer from rare diseases, such as nontuberculous mycobacteria (NTM) lung disease and pulmonary arterial hypertension (PAH), face multiple hurdles in finding effective treatments. Insmed is addressing the critical, unmet needs of these orphan patient populations. The company’s lead product candidate is an inhaled antibiotic that is in late-stage clinical development for serious lung infections caused by NTM. There are currently no approved therapies in the United States or European Union for NTM lung disease. Current guideline-based multi-drug regimens are poorly tolerated with limited clinical evidence of efficacy. Insmed’s advanced proprietary liposomal technology enables delivery of a potent antibiotic via inhalation using charge-neutral liposomes that are taken up by the lung macrophages where the NTM infection resides.
“Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases,” said Will Lewis, President and CEO at Insmed. “Patients are at the center of everything we do, and each of us brings a personal passion for advancing innovative therapies that can transform the lives of patients with rare diseases around the world.”
The company is also developing INS1009, a nebulized treprostinil prodrug for the treatment of PAH. Insmed’s innovative focus is on the convenient dosing regimen, enhanced drug delivery and lower systemic drug exposure, which exemplifies its priority to improve patient comfort and care. Insmed has applied its product design, drug development and sustained-release formulation expertise to advance INS1009 and other pipeline products with the goal of addressing current limitations of inhaled prostacyclin therapies.
The pillars that support Insmed’s dedication to patients are grounded in a corporate culture that fosters innovation and creativity, as well as entrepreneurial spirit. Insmed team members work with purpose to serve patients in need, maintain innovative excellence and take personal accountability for the company’s performance. Insmed instills a company-wide focus on issues critical to the company’s success, and encourages employees to work with mutual respect, openness and teamwork.
“Insmed employees are expected to work on small, cross-functional teams that are empowered to make their own decisions,” said Nicole Schaeffer, Senior Vice President of Human Resources and Corporate Services. “We look to recruit exceptional talent that likes to roll-up-their-sleeves, collaborate and think outside of the box.”
The company believes that putting patients first will strengthen the foundation for long-term success and shareholder value. Furthermore, the belief that the company can make a difference in the lives of patients with rare diseases is the foundation of Insmed’s values and purpose, which acts as a compass for setting priorities and weighing difficult decisions.
“It is our dedication to serving patients that propels our company to the forefront of innovation and entrepreneurship,” added Lewis. “Our focus on ingenuity and freedom of expression has not only led to the company’s novel approach to developing orphan products for rare diseases, but it remains the driving force behind our team of committed research and development professionals.”